{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:46:35Z","timestamp":1792597595453,"version":"4.5.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01119","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T04:14:19Z","timestamp":1570076059000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson\u2019s Disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Yoshio","family":"Goshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Masukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aderemi Caleb","family":"Aladeokin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.physbeh.2011.04.055","article-title":"Pathological behaviors provoked by dopamine agonist therapy of Parkinson\u2019s disease","volume":"104","author":"Ahlskog","year":"2011","journal-title":"Physiol. Behav."},{"key":"B2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/jnc.13125","article-title":"Effects of the beta-adrenergic receptor antagonist propranolol on dyskinesia and l-DOPA\u2013induced striatal DA efflux in the hemi-parkinsonian rat","volume":"134","author":"Bhide","year":"2015","journal-title":"J. Neurochem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1517\/14656566.6.14.2393","article-title":"Current pharmacotherapy for acromegaly: a review","volume":"6","author":"Biermasz","year":"2005","journal-title":"Expert Opin. Pharmacother"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1046\/j.1471-4159.1997.69062413.x","article-title":"Adrenomedullary secretion of DOPA, catecholamines, catechol metabolites, and neuropeptides","volume":"69","author":"Chritton","year":"1997","journal-title":"J. Neurochem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-4613-0759-4_15","article-title":"Monoamine oxidase, hydrogen peroxide, and Parkinson\u2019s disease","volume":"45","author":"Cohen","year":"1987","journal-title":"Adv. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000067968","article-title":"Dopaminergic modulation of visual-spatial working memory in Parkinson\u2019s disease","volume":"15","author":"Costa","year":"2003","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1167\/iovs.16-21128","article-title":"Identification of novel G protein\u2013coupled receptor 143 ligands as pharmacologic tools for investigating X-linked ocular albinism","volume":"58","author":"De Filippo","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamaneurol.2017.1125","article-title":"Association of autonomic dysfunction with disease progression and survival in Parkinson disease","volume":"74","author":"De Pablo-Fernandez","year":"2017","journal-title":"JAMA Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson\u2019s disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.phrs.2017.01.008","article-title":"An update on the physiological and therapeutic relevance of GPCR oligomers","volume":"117","author":"Farran","year":"2017","journal-title":"Pharmacol. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.tips.2015.01.002","article-title":"The GPCR heterotetramer: challenging classical pharmacology","volume":"36","author":"Ferre","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/pr.113.008052","article-title":"G protein\u2013coupled receptor oligomerization revisited: functional and pharmacological perspectives","volume":"66","author":"Ferre","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1124\/mol.107.043885","article-title":"Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization","volume":"74","author":"Fiorentini","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.brainres.2015.01.020","article-title":"Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs","volume":"1602","author":"Fukuda","year":"2015","journal-title":"Brain Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00894-011-1228-8","article-title":"Structural insights into human GPCR protein OA1: a computational perspective","volume":"18","author":"Ghosh","year":"2012","journal-title":"J. Mol. Model"},{"key":"B17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1212\/WNL.42.2.333","article-title":"Motor blocks in Parkinson\u2019s disease","volume":"42","author":"Giladi","year":"1992","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1124\/jpet.103.049270","article-title":"Sources and significance of plasma levels of catechols and their metabolites in humans","volume":"305","author":"Goldstein","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1476-5381.1986.tb11139.x","article-title":"Biphasic actions of l-DOPA on the release of endogenous noradrenaline and dopamine from rat hypothalamic slices","volume":"89","author":"Goshima","year":"1986","journal-title":"Br. J. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1111\/j.1471-4159.1988.tb02470.x","article-title":"Transmitter-like release of endogenous 3,4-dihydroxyphenylalanine from rat striatal slices","volume":"50","author":"Goshima","year":"1988","journal-title":"J. Neurochem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1254\/jjp.55.93","article-title":"Nanomolar l-DOPA facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)\u2013treated C57 black mice, an animal model for Parkinson\u2019s disease","volume":"55","author":"Goshima","year":"1991","journal-title":"Jpn J. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1254\/jphs.14R03CR","article-title":"Cardiovascular actions of DOPA mediated by the gene product of ocular albinism 1","volume":"126","author":"Goshima","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"B23","first-page":"466","article-title":"L-Dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine\u2013induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices","volume":"258","author":"Goshima","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0006-8993(93)90631-V","article-title":"l-DOPA induces Ca(2+)-dependent and tetrodotoxin-sensitive release of endogenous glutamate from rat striatal slices","volume":"617","author":"Goshima","year":"1993","journal-title":"Brain Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neures.2018.12.004","article-title":"Immunoreactivity of a G protein\u2013coupled l-DOPA receptor GPR143, in Lewy bodies","volume":"148","author":"Goshima","year":"2018","journal-title":"Neurosci. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/ana.22423","article-title":"Therapies for dopaminergic-induced dyskinesias in Parkinson disease","volume":"69","author":"Gottwald","year":"2011","journal-title":"Ann. Neurol."},{"key":"B27","first-page":"644","article-title":"Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro","volume":"14","author":"Graham","year":"1978","journal-title":"Mol. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/bph.12459","article-title":"The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii","volume":"171","author":"Hiroshima","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6461907","article-title":"Levodopa-induced dyskinesia is related to indirect pathway medium spiny neuron excitotoxicity: a hypothesis based on an unexpected finding","volume":"2016","author":"Ivanova","year":"2016","journal-title":"Parkinsons Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0304-3940(92)90280-K","article-title":"Production of specific antibody against l-DOPA and its ultrastructural localization of immunoreactivity in the house-shrew (Suncus murinus) lateral habenular nucleus","volume":"143","author":"Karasawa","year":"1992","journal-title":"Neurosci. Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0304-3940(92)90090-T","article-title":"Evidence for l-DOPA systems responsible for cardiovascular control in the nucleus tractus solitarii of the rat","volume":"140","author":"Kubo","year":"1992","journal-title":"Neurosci. Lett."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1093\/brain\/119.6.2121","article-title":"Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson\u2019s disease patients at different levodopa plasma levels","volume":"119","author":"Kulisevsky","year":"1996","journal-title":"Brain"},{"key":"B33","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.tips.2017.05.006","article-title":"Folding underlies bidirectional role of GPR37\/Pael-R in Parkinson disease","volume":"38","author":"Leinartaite","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"B34","first-page":"453","article-title":"The neurochemistry of Parkinson\u2019s disease: effect of L-DOPA therapy","volume":"195","author":"Lloyd","year":"1975","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0060236","article-title":"l-DOPA is an endogenous ligand for OA1","volume":"6","author":"Lopez","year":"2008","journal-title":"PLoS Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000439532","article-title":"l-DOPA stimulates cortisol secretion through adrenocorticotropic hormone release in short children","volume":"84","author":"Marakaki","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"B37","first-page":"S32","article-title":"Problems with long-term levodopa therapy for Parkinson\u2019s disease","volume":"17","author":"Marsden","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1172\/jci.insight.90903","article-title":"l-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor","volume":"2","author":"Masukawa","year":"2017","journal-title":"JCI Insight"},{"key":"B39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neures.2014.07.008","article-title":"Localization of ocular albinism-1 gene product GPR143 in the rat central nervous system","volume":"88","author":"Masukawa","year":"2014","journal-title":"Neurosci. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.tips.2011.05.006","article-title":"Asymmetry of GPCR oligomers supports their functional relevance","volume":"32","author":"Maurice","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"9529","DOI":"10.1073\/pnas.1219004110","article-title":"GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin","volume":"110","author":"Meyer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0165-6147(93)90082-U","volume":"14","author":"Misu","year":"1993","journal-title":"Trends Pharmacol. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0301-0082(96)00025-1","article-title":"Neurobiology of l-DOPAergic systems","volume":"49","author":"Misu","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0165-6147(02)02013-8","article-title":"Is DOPA a neurotransmitter","volume":"23","author":"Misu","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neuroscience.2017.11.053","article-title":"alpha1b-Adrenergic receptor localization and relationship to the D1-dopamine receptor in the rat nucleus accumbens","volume":"371","author":"Mitrano","year":"2018","journal-title":"Neuroscience"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S0024-3205(99)00031-4","article-title":"Some interactions of l-DOPA and its related compounds with glutamate receptors","volume":"64","author":"Miyamae","year":"1999","journal-title":"Life Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0006-8993(88)90793-7","article-title":"Visualization of L-dihydroxyphenylalanine in rat brain by using specific antibodies","volume":"451","author":"Mons","year":"1988","journal-title":"Brain Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/WNF.0b013e318219dad0","article-title":"Levodopa induces synthesis of nerve growth factor and growth hormone in patients with Parkinson disease","volume":"34","author":"Muller","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ana.20064","article-title":"Pael-R is accumulated in Lewy bodies of Parkinson\u2019s disease","volume":"55","author":"Murakami","year":"2004","journal-title":"Ann. Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.410430504","article-title":"Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions","volume":"43","author":"Murer","year":"1998","journal-title":"Ann. Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00702-016-1596-4","article-title":"Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson\u2019s disease (PD): historical overview and future prospects","volume":"123","author":"Nagatsu","year":"2016","journal-title":"J. Neural Transm. (Vienna)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1471-4159.1992.tb09306.x","article-title":"Transmitter-like basal and K(+)-evoked release of 3,4-dihydroxyphenylalanine from the striatum in conscious rats studied by microdialysis","volume":"58","author":"Nakamura","year":"1992","journal-title":"J. Neurochem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0304-3940(94)90229-1","article-title":"Non-effective dose of exogenously applied l-DOPA itself stereoselectively potentiates postsynaptic D2 receptor\u2013mediated locomotor activities of conscious rats","volume":"170","author":"Nakamura","year":"1994","journal-title":"Neurosci. Lett."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1242\/jcs.02930","article-title":"An unconventional dileucine-based motif and a novel cytosolic motif are required for the lysosomal and melanosomal targeting of OA1","volume":"119","author":"Piccirillo","year":"2006","journal-title":"J. Cell Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/2045125312470130","article-title":"Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson\u2019s disease: a review","volume":"3","author":"Poletti","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/mds.23714","article-title":"Milestones in Parkinson\u2019s disease therapeutics","volume":"26","author":"Rascol","year":"2011","journal-title":"Mov. Disord."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.biocel.2010.03.023","article-title":"Signaling pathways in melanosome biogenesis and pathology","volume":"42","author":"Schiaffino","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/12715","article-title":"Ocular albinism: evidence for a defect in an intracellular signal transduction system","volume":"23","author":"Schiaffino","year":"1999","journal-title":"Nat. Genet."},{"key":"B59","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.neuropharm.2006.01.001","article-title":"L-3,4-Dihydroxyphenylalanine\u2013induced c-Fos expression in the CNS under inhibition of central aromatic l-amino acid decarboxylase","volume":"50","author":"Shimamura","year":"2006","journal-title":"Neuropharmacology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/00001756-199404000-00039","article-title":"l-DOPA increases nigral production of hydroxyl radicals in vivo: potential l","volume":"5","author":"Smith","year":"1994","journal-title":"Neuroreport"},{"key":"B61","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0006-8993(95)00870-V","article-title":"l-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson\u2019s model rats","volume":"698","author":"Ueda","year":"1995","journal-title":"Brain Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0753-3322(96)82617-5","article-title":"Supersensitization of neurochemical responses by l-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson\u2019s disease model rats","volume":"49","author":"Ueda","year":"1995","journal-title":"Biomed. Pharmacother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jphs.2016.08.005","article-title":"l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice","volume":"132","author":"Ueda","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","article-title":"Randomized delayed-start trial of levodopa in Parkinson\u2019s disease","volume":"380","author":"Verschuur","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1124\/jpet.108.144097","article-title":"Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\u2013lesioned macaques","volume":"328","author":"Visanji","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","article-title":"Impulse control disorders and levodopa-induced dyskinesias in Parkinson\u2019s disease: an update","volume":"16","author":"Voon","year":"2017","journal-title":"Lancet Neurol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s10072-015-2253-7","article-title":"Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson\u2019s disease: a meta-analysis","volume":"36","author":"Xie","year":"2015","journal-title":"Neurol. Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0896-6273(03)00143-0","article-title":"Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila","volume":"37","author":"Yang","year":"2003","journal-title":"Neuron"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1167\/iovs.08-1806","article-title":"Involvement of OA1, an intracellular GPCR, and G alpha i3, its binding protein, in melanosomal biogenesis and optic pathway formation","volume":"49","author":"Young","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0306-4522(94)90321-2","article-title":"Baroreceptor-aortic nerve-mediated release of endogenous L-3,4-dihydroxyphenylalanine and its tonic depressor function in the nucleus tractus solitarii of rats","volume":"62","author":"Yue","year":"1994","journal-title":"Neuroscience"},{"key":"B71","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.brainres.2006.04.019","article-title":"Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson\u2019s disease","volume":"1095","author":"Zhang","year":"2006","journal-title":"Brain Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neulet.2004.06.014","article-title":"Determination of exocytosis mechanisms of DOPA in rat striatum using in vivo microdialysis","volume":"367","author":"Zhu","year":"2004","journal-title":"Neurosci. Lett."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01119\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T04:14:22Z","timestamp":1570076062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01119\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":72,"alternative-id":["10.3389\/fphar.2019.01119"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01119","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,3]]},"article-number":"1119"}}